Life science REITs occupy a distinctive niche in commercial real estate: they own the laboratory and research buildings where biotechnology, pharmaceutical, and research tenants do their work. Unlike ordinary office space, lab space is purpose-built — it needs advanced ventilation, specialized power and HVAC, vibration control, and infrastructure that's expensive and difficult to replicate, which tends to support higher rents and stickier tenants. Demand is driven by the growth of biotech and pharma research and development, and supply is concentrated in a few innovation clusters — places like Boston and Cambridge, the San Francisco Bay Area, and San Diego — where talent, universities, capital, and companies congregate. The trade-off is that tenant demand is tied closely to biotech funding cycles: when venture capital and research funding are flowing, demand for lab space is strong; when funding tightens, demand can soften and vacancy can rise. This guide explains what life science REITs own, the biotech and pharma demand, the economics of specialized lab space, the funding-cycle risk, and how to evaluate a life science REIT. Demand, returns, and outlook are discussed in general, non-promissory terms — past performance doesn't guarantee future results, and you should verify current conditions; this is educational information, not investment advice.
What Life Science REITs Own
Life science REITs own laboratory and research real estate — purpose-built buildings designed for scientific work rather than ordinary office use. These are life-science buildings leased to biotechnology companies, pharmaceutical firms, and research organizations that need wet labs, dry labs, and specialized research space. The defining feature is that the buildings are engineered for science: they include advanced HVAC and ventilation systems, redundant power, specialized plumbing for lab gases and water, vibration control for sensitive instruments, and higher ceiling heights and floor loads than a typical office. This makes lab space fundamentally different from — and more expensive to build than — conventional office space.
Geographically, life science real estate is highly clustered. Most of it sits in a handful of innovation hubs where research universities, talent, venture capital, and established companies congregate — notably the Boston and Cambridge area, the San Francisco Bay Area, and San Diego, along with a few other emerging clusters. This clustering exists because life-science companies want to be near the talent, collaborators, and capital that drive the industry, so the real estate concentrates where the ecosystem is strongest. As a result, a life science REIT's portfolio is often concentrated in these markets, and the value of its buildings is tied to the health of those specific clusters.
So a life science REIT owns purpose-built lab and research buildings — engineered for science and clustered in a few innovation hubs — leased to biotech, pharma, and research tenants. So understanding what they own frames the demand and risks. Life science REITs own specialized laboratory and research real estate, built with advanced ventilation, power, and infrastructure for scientific work and concentrated in innovation clusters like Boston/Cambridge, the San Francisco Bay Area, and San Diego, leased to biotech, pharma, and research tenants. The buildings are costly, specialized, and location-dependent. Understanding what they own frames the rest. A life science REIT owns purpose-built lab and research space clustered in innovation hubs and leased to biotech, pharma, and research tenants.
Biotech & Pharma Demand
Demand for life science real estate is driven by the growth of biotech and pharmaceutical research and development. As biotechnology and pharma companies expand their pipelines, scale up research, and form new ventures, they need more laboratory and research space to house scientists, instruments, and experiments. The long-run drivers are powerful: an aging population, advances in genomics and drug discovery, and steady investment in life sciences all tend to support demand for lab space over time. When the industry is growing and well-funded, demand for purpose-built lab space in the major clusters can be robust.
This demand has a particular character. Life-science tenants range from large, creditworthy pharmaceutical companies and established biotechs to small, early-stage startups still developing their first products — so tenant credit and stage vary widely across a portfolio. Larger tenants offer stronger credit and stability; smaller, earlier-stage tenants offer growth but more risk, since many are pre-revenue and depend on outside funding. The clustering effect reinforces demand: companies want to be where the talent, universities, and collaborators are, so the established hubs tend to attract a disproportionate share of activity. So demand is real and structurally supported, but its strength varies with the health and funding of the biotech and pharma industry.
So biotech and pharma demand — driven by R&D growth, an aging population, and scientific advances, and concentrated in innovation hubs — is the engine behind life science REITs, though it varies with industry health. So understanding demand frames the sector's appeal. Biotech and pharma demand for lab space comes from research-and-development growth, demographic and scientific tailwinds, and the clustering of companies near talent and capital, with tenants ranging from large, creditworthy firms to early-stage, funding-dependent startups. The demand is structurally supported but cyclical. Understanding it frames the sector's appeal. Demand for life science space is driven by biotech and pharma R&D growth and clustering, with tenants spanning strong-credit firms and riskier early-stage startups.
Lab space sells the ecosystem as much as the square footage: biotech tenants pay to be inside a cluster of talent, universities, and capital — which is why demand concentrates in just a few markets.
Specialized Lab Space
The specialized nature of lab space is what gives life science REITs much of their economic appeal. Purpose-built laboratories require advanced infrastructure — sophisticated HVAC and ventilation to handle fume hoods and air exchanges, redundant and high-capacity power, specialized gas and water systems, vibration isolation for sensitive equipment, and structural features ordinary offices lack. This infrastructure is expensive to build and difficult to retrofit into conventional space, which limits supply and raises the replacement cost of existing lab buildings. As a result, well-located, modern lab space tends to command higher rents than comparable office space.
This specialization also makes tenants sticky. Once a biotech or pharma company has built out a lab — installing equipment, validating clean rooms, and configuring the space for its research — moving is costly and disruptive, both financially and to ongoing experiments. That high cost of relocation gives tenants a strong incentive to stay and renew, which can support occupancy and rent stability for the landlord. The combination of hard-to-replicate space, limited supply, premium rents, and sticky tenants is the core investment case for the sector. The trade-off is that highly specialized space can be harder to re-lease to a non-lab tenant if a life-science tenant leaves, since not every business needs (or wants to pay for) lab infrastructure.
So specialized lab space — costly to build, hard to replicate, commanding premium rents, and retaining sticky tenants — is the economic heart of life science REITs, with re-leasing the main caveat. So understanding the space explains the rents. Specialized lab space requires advanced ventilation, power, and infrastructure that's expensive and hard to replicate, which limits supply, supports premium rents, and makes tenants sticky because relocating a built-out lab is costly and disruptive. The caveat is that highly specialized space can be harder to re-lease to non-lab users. Understanding the space explains the economics. Specialized, purpose-built lab space commands premium rents and retains sticky tenants because it's costly to build and disruptive to leave.
Funding-Cycle Risk
The defining risk of life science REITs is funding-cycle risk. Tenant demand for lab space is tied closely to the availability of biotech venture capital and research funding. When venture capital is abundant and the biotech IPO and financing markets are open, startups raise money, expand, and lease more lab space, and demand is strong. But when funding tightens — during a biotech downturn, a pullback in venture capital, or a difficult financing environment — early-stage and pre-revenue tenants may slow expansion, cut space, or fail outright, which reduces demand and can push vacancy higher. Because so many life-science tenants depend on outside capital rather than current profits, the sector's demand is unusually sensitive to funding conditions.
This funding sensitivity is what makes life science REITs more cyclical than their specialized, high-rent space might suggest. A wave of new lab supply delivered into a softening funding environment can be especially difficult, because rising vacancy and falling demand can pressure rents and occupancy at the same time. The risk is concentrated among smaller, earlier-stage tenants; larger, well-capitalized pharma and established biotech tenants are more resilient through downturns. So a portfolio's exposure to funding-cycle risk depends heavily on its tenant mix — the more it leans on early-stage, funding-dependent tenants and on new, speculative supply, the more sensitive it is to the biotech funding cycle.
So funding-cycle risk — demand tied to biotech venture and research funding, with downturns reducing demand and raising vacancy, concentrated in early-stage tenants — is the central vulnerability of life science REITs. So understanding it is essential. Funding-cycle risk arises because lab-space demand tracks biotech venture capital and research funding: when funding tightens, early-stage and pre-revenue tenants slow, contract, or fail, reducing demand and raising vacancy, and new supply into a downturn worsens it. The risk concentrates in smaller, funding-dependent tenants. Understanding it is essential. Funding-cycle risk — demand tied to biotech funding, with downturns lifting vacancy — is the defining vulnerability, concentrated in early-stage tenants.
- Life science REITs own purpose-built lab and research space — engineered for science and clustered in innovation hubs like Boston/Cambridge, the Bay Area, and San Diego.
- Demand is driven by biotech and pharma R&D growth, with tenants ranging from large, creditworthy firms to riskier early-stage startups.
- Specialized lab space is costly to build, hard to replicate, commands premium rents, and makes tenants sticky — but can be harder to re-lease to non-lab users.
- Funding-cycle risk is the defining vulnerability: demand tracks biotech venture and research funding, so downturns can reduce demand and raise vacancy.
Supply Pipeline and Market Concentration
Beyond funding, the supply pipeline is a crucial factor for life science REITs, because lab-space economics depend on the balance between demand and new construction. When developers race to build new lab buildings in popular clusters — often in response to a period of strong demand — a large pipeline of new supply can come online over several years. If that supply arrives while demand is still strong, it may be absorbed; but if it lands during a funding downturn, the combination of rising vacancy and abundant new space can pressure rents and occupancy across a market. So tracking the construction pipeline in each key cluster is essential to understanding where rents and vacancy may be headed.
Market concentration compounds this. Because life science real estate is concentrated in a few hubs, a life science REIT's fortunes are tied to the health of those specific markets — their funding climate, talent pools, and supply pipelines. A REIT heavily concentrated in a single cluster is more exposed to that market's supply-and-demand swings than one diversified across several hubs. Some REITs also focus on the strongest sub-markets and on properties anchored by larger, creditworthy tenants, which can cushion against cluster-specific shocks. So both the supply pipeline and the degree of market concentration shape a life science REIT's risk, alongside the funding cycle and tenant mix.
So the supply pipeline and market concentration — the pace of new lab construction in each hub and how concentrated a REIT is in particular clusters — are key factors layered on top of funding-cycle risk. So they belong in any evaluation. Supply pipeline and market concentration matter because new lab construction can overwhelm a market — especially during a funding downturn — and because life science real estate's concentration in a few hubs ties a REIT's fortunes to those specific markets' supply, demand, and funding conditions. Diversification across clusters and strong sub-markets can cushion shocks. Understanding supply and concentration rounds out the picture. The supply pipeline and a REIT's market concentration shape its risk: new construction can pressure rents, and concentration in one hub raises exposure to that market.
Lab space lives or dies on the balance between two things you can actually track: how much new construction is coming online in each cluster, and how freely biotech funding is flowing to fill it.
Evaluating Life Science REITs
Evaluating a life science REIT begins with location and cluster quality, because the sector is so geographically concentrated. Which innovation hubs is the REIT in, how deep and durable is each cluster's ecosystem of talent, universities, and capital, and how diversified is the portfolio across markets? A REIT anchored in strong, established clusters with diversified exposure is generally better positioned than one concentrated in a single, less-proven market. Next, assess tenant credit and stage: what share of rent comes from large, creditworthy pharma and established biotech versus small, early-stage, funding-dependent startups? A tenant base weighted toward stronger credits is more resilient through funding downturns.
Then examine the supply pipeline in each key market — how much new lab space is being delivered, and how does it compare with demand — since oversupply into a soft funding environment is a major risk. Consider the REIT's leverage and balance sheet, the quality and modernity of its buildings, lease terms and tenant retention, and how exposed it is to funding-cycle risk through its tenant mix. Finally, treat demand and outlook as general and non-promissory: biotech funding is cyclical, distributions aren't guaranteed, and share prices fluctuate. Past performance doesn't guarantee future results, and current cluster conditions, funding climate, and supply pipelines should be verified independently rather than assumed from a strong recent period.
So evaluating a life science REIT means weighing cluster and location quality, tenant credit and stage, the supply pipeline, leverage, building quality, and funding-cycle exposure. So a disciplined framework guides the analysis. Evaluating life science REITs centers on cluster and location quality, tenant credit and development stage, the new-supply pipeline in each market, the REIT's leverage and building quality, and exposure to funding-cycle risk through the tenant mix. Strong clusters and creditworthy tenants anchor resilience, while funding sensitivity and oversupply are the key risks. Understanding this framework guides a disciplined evaluation. Evaluate a life science REIT by cluster quality, tenant credit and stage, the supply pipeline, leverage, building quality, and funding-cycle exposure — treating demand as non-promissory.
How Baker 1031 Helps You Evaluate Life Science REITs
Baker 1031 Investments helps investors understand life science REITs — the specialized lab and research space they own, the biotech and pharma demand behind them, why purpose-built lab space commands premium rents and sticky tenants, the funding-cycle risk that defines the sector, the supply pipeline, and how to evaluate a life science REIT — so you can decide whether the sector fits your goals and, if so, access suitable offerings.
REIT and non-traded-REIT interests and related securities are offered through the broker-dealer, Aurora Securities, Inc. (member FINRA/SIPC), and any recommendation follows a suitability review — non-traded and private REITs typically require accredited or otherwise suitable investors, while publicly traded REITs trade through ordinary brokerage accounts. Baker 1031 does not provide tax or legal advice; your CPA and attorney handle your specific tax situation, including how REIT dividends are taxed. We help you understand the life-science-REIT structure, weigh cluster quality, tenant credit and stage, the supply pipeline, leverage, and funding-cycle exposure, and access suitable offerings when appropriate. We discuss demand, returns, and outlook in general, non-promissory terms — yields and returns are never promised, past performance doesn't guarantee future results, and you should verify current conditions, including the biotech funding climate and supply pipelines. Distributions can be cut and share prices fluctuate. Our role is to help you evaluate life science REITs clearly and invest only when suitable for your goals and risk tolerance.
Frequently Asked Questions
What is a life science REIT?
A life science REIT is a Real Estate Investment Trust that owns specialized laboratory and research real estate — purpose-built life-science buildings — and leases that space to biotechnology, pharmaceutical, and research tenants. Unlike ordinary office space, lab space is engineered for science: it includes advanced HVAC and ventilation, high-capacity and redundant power, specialized gas and water systems, vibration control for sensitive instruments, and structural features ordinary offices lack. This makes the buildings expensive to construct and difficult to replicate. Life science real estate is also highly clustered, concentrated in a few innovation hubs like Boston and Cambridge, the San Francisco Bay Area, and San Diego, where research universities, talent, venture capital, and companies congregate. The REIT collects rent from its lab tenants and distributes most of its income to shareholders under the usual REIT rules. So a life science REIT is a specialized landlord owning hard-to-replicate lab and research buildings, clustered in innovation hubs, and leased to biotech, pharma, and research organizations.
What do life science REITs own?
Life science REITs own purpose-built laboratory and research buildings designed for scientific work rather than ordinary office use. These properties contain wet labs, dry labs, and research space, and they're engineered with advanced ventilation and HVAC to handle fume hoods and frequent air exchanges, redundant high-capacity power, specialized plumbing for lab gases and water, vibration isolation for sensitive equipment, and higher floor loads and ceiling heights than typical offices. This infrastructure is what distinguishes lab space from conventional commercial real estate and makes it far more expensive to build. Geographically, the real estate is concentrated in a handful of innovation clusters — notably Boston/Cambridge, the San Francisco Bay Area, and San Diego, plus some emerging hubs — because life-science companies want to be near talent, universities, collaborators, and capital. So life science REITs own specialized, costly-to-build lab and research buildings clustered in the leading innovation markets, leased to biotech, pharma, and research tenants who need that specialized infrastructure.
What drives demand for life science real estate?
Demand for life science real estate is driven primarily by the growth of biotechnology and pharmaceutical research and development. As biotech and pharma companies expand their pipelines, scale up research, and form new ventures, they need more lab and research space for scientists, instruments, and experiments. Longer-run tailwinds support this demand: an aging population, advances in genomics and drug discovery, and ongoing investment in the life sciences. The clustering effect reinforces it — companies want to be near the talent, universities, and collaborators concentrated in a few innovation hubs, so activity and demand concentrate there. Tenants range from large, creditworthy pharma and established biotech firms to small, early-stage startups, so the strength and resilience of demand vary with the industry's health and, critically, its funding. When biotech is growing and well-funded, demand for lab space can be robust; when funding tightens, demand can soften. So demand is structurally supported but cyclical, tied closely to biotech and pharma activity and funding.
Why does specialized lab space command higher rents?
Specialized lab space commands higher rents than ordinary office space because it's far more expensive to build and much harder to replicate. Purpose-built laboratories require advanced HVAC and ventilation for fume hoods and air exchanges, redundant high-capacity power, specialized gas and water systems, vibration isolation for sensitive instruments, and stronger structural features — infrastructure that conventional offices lack and that's costly to retrofit. This raises the replacement cost of lab buildings and limits the supply of high-quality space, both of which support premium rents. The specialization also makes tenants sticky: once a biotech or pharma company has built out and validated a lab, relocating is expensive and disruptive to ongoing experiments, so tenants have strong incentives to stay and renew, supporting occupancy and rent stability. The trade-off is that highly specialized space can be harder to re-lease to a non-lab business if a tenant leaves. So premium rents reflect costly, hard-to-replicate infrastructure, limited supply, and sticky tenants who find it disruptive to move.
What is funding-cycle risk for life science REITs?
Funding-cycle risk is the defining vulnerability of life science REITs. Tenant demand for lab space is tied closely to the availability of biotech venture capital and research funding, because so many life-science tenants — especially smaller, early-stage ones — are pre-revenue and depend on outside capital rather than profits. When venture capital is abundant and biotech financing markets are open, startups raise money, expand, and lease more lab space, so demand is strong. But when funding tightens — during a biotech downturn or a pullback in venture capital — early-stage tenants may slow expansion, give back space, or fail, reducing demand and pushing vacancy higher. This makes the sector more cyclical than its specialized, high-rent space might suggest, and the risk is concentrated among smaller, funding-dependent tenants; large, well-capitalized pharma is more resilient. So funding-cycle risk means lab-space demand rises and falls with biotech funding, and a portfolio's exposure depends heavily on how much it leans on early-stage tenants and speculative new supply.
Where is life science real estate concentrated?
Life science real estate is highly concentrated in a few innovation hubs where the ingredients of the industry come together. The leading clusters are the Boston and Cambridge area, the San Francisco Bay Area, and San Diego, with a handful of other emerging markets. This concentration exists because life-science companies want to locate near research universities, scientific talent, venture capital, and the collaborators and suppliers that make up the ecosystem — so the real estate concentrates where that ecosystem is strongest. For a life science REIT, this clustering means its portfolio is often concentrated in these specific markets, and the value of its buildings is tied to the health of those clusters: their funding climate, talent pools, and supply pipelines. A REIT heavily concentrated in a single cluster is more exposed to that market's swings than one diversified across several hubs. So when evaluating a life science REIT, the quality and diversity of the clusters it operates in is a central consideration, because geography drives much of the sector's risk and opportunity.
Are life science REITs a good investment?
Whether a life science REIT fits depends on your goals and risk tolerance, and the sector has both appeal and distinctive risks. On the appeal side, it owns hard-to-replicate, specialized lab space that commands premium rents and retains sticky tenants, and it's supported by long-run demand drivers like an aging population and advances in biotech and pharma research. On the risk side, the sector is unusually cyclical because demand is tied to biotech venture and research funding, so downturns can reduce demand and raise vacancy; the real estate is concentrated in a few hubs; new supply can pressure rents; and many tenants are early-stage and funding-dependent. As with any REIT, distributions aren't guaranteed and share prices fluctuate. So a life science REIT can offer exposure to a specialized, structurally supported sector, but it carries real, sector-specific risk that should be understood and sized appropriately. Past performance doesn't guarantee future results, and current funding and supply conditions should be verified rather than assumed.
How is lab space different from office space?
Lab space differs fundamentally from office space in design, cost, and economics. A laboratory is engineered for science: it needs advanced HVAC and ventilation to handle fume hoods and frequent air exchanges, redundant high-capacity power, specialized plumbing for lab gases and water, vibration isolation for sensitive instruments, and stronger floors and higher ceilings than a typical office. This infrastructure makes lab space far more expensive to build and difficult to retrofit into conventional space, which limits supply and supports higher rents than comparable office space. Lab space also makes tenants sticky — once a company builds out and validates a lab, moving is costly and disruptive to research, so tenants tend to stay and renew. By contrast, office space is cheaper to build, more interchangeable, and easier to re-lease to a wide range of tenants. The trade-off for lab space is that it can be harder to repurpose for non-lab users. So lab space is specialized, costly, premium-rent, and sticky, where office space is general-purpose and flexible.
What happens to life science REITs in a biotech downturn?
In a biotech downturn, life science REITs can face real pressure, because the sector's demand is tied to biotech venture capital and research funding. When funding tightens — venture capital pulls back, IPO and financing markets cool — early-stage and pre-revenue tenants may slow expansion, give back space, or fail outright, which reduces demand for lab space and can push vacancy higher. If a wave of new lab supply is being delivered at the same time, the combination of rising vacancy and abundant new space can pressure rents and occupancy across a market. The impact is concentrated among smaller, funding-dependent tenants; larger, well-capitalized pharma and established biotech tenants are generally more resilient and continue paying rent. So a downturn's effect on a particular REIT depends heavily on its tenant mix and its exposure to speculative new supply — a portfolio anchored by creditworthy tenants in strong clusters is more resilient than one leaning on early-stage tenants. So biotech downturns are the sector's main stress test, with effects varying by portfolio quality.
How does the supply pipeline affect life science REITs?
The supply pipeline — the amount of new lab space under construction and being delivered in each market — is a crucial factor for life science REITs, because lab-space economics depend on the balance between demand and new supply. When developers build aggressively in popular clusters, often after a period of strong demand, a large pipeline can come online over several years. If that new space is delivered while demand remains strong, it may be absorbed without much trouble. But if it lands during a funding downturn, the combination of rising vacancy and abundant new supply can pressure rents and occupancy across the market, sometimes sharply. Because life science real estate is concentrated in a few hubs, an oversupplied cluster can weigh on any REIT exposed to it. So tracking the construction pipeline in each key market is essential to understanding where rents and vacancy may be headed. A REIT that built or bought into a market just as a large supply wave arrived can face headwinds, while disciplined markets with limited new supply tend to hold up better.
How do I evaluate the tenants of a life science REIT?
Start by assessing tenant credit and development stage, because life-science tenants range widely. Large, creditworthy pharmaceutical companies and established, well-funded biotechs offer stronger credit and stability, while small, early-stage startups offer growth but more risk, since many are pre-revenue and depend on outside funding. Look at what share of the REIT's rent comes from each group — a portfolio weighted toward stronger credits is more resilient through funding downturns, while one leaning on early-stage tenants is more exposed to funding-cycle risk. Examine lease terms and tenant retention, since sticky, long-term tenants in well-located buildings support stable income. Consider the diversity of the tenant base across companies, stages, and clusters, so that trouble at any one tenant or in any one market has a limited effect. Finally, weigh how the tenant mix interacts with the supply pipeline and funding climate in each cluster. So evaluating life-science-REIT tenants means weighing credit, stage, lease terms, retention, and diversification together, with special attention to funding-dependent tenants.
Are life science REITs cyclical?
Yes — life science REITs are more cyclical than their specialized, high-rent space might suggest, primarily because of funding-cycle risk. Tenant demand for lab space is tied to biotech venture capital and research funding, and many life-science tenants, especially early-stage ones, depend on outside capital rather than current profits. So when funding is abundant, demand for lab space is strong; when funding tightens during a biotech downturn, demand can soften, early-stage tenants can contract or fail, and vacancy can rise. The cyclicality is amplified when new lab supply is delivered into a weakening funding environment, since rising vacancy and abundant supply can pressure rents and occupancy at once. That said, the sector also has structural, long-run demand drivers — an aging population and advances in biotech and pharma research — that support it over time, and larger, well-capitalized tenants are more resilient through cycles. So life science REITs combine durable long-term demand with real short-term cyclicality tied to biotech funding, and a portfolio's tenant mix and supply exposure determine how cyclical it actually is.
How do interest rates affect life science REITs?
Like most REITs, life science REITs are sensitive to interest rates. Higher rates can pressure REIT share prices because income-oriented REITs compete with bonds for investors, so when yields on bonds rise, the relative appeal of a REIT's distribution can decline even if its rents are unchanged. Higher borrowing costs also make it more expensive for REITs to finance acquisitions and development, which can slow growth and weigh on the economics of new lab projects. For life science REITs specifically, interest rates can interact with the sector's funding-cycle risk: tighter financial conditions often coincide with a harder biotech funding environment, which can soften tenant demand at the same time that the REIT's own cost of capital rises. The specialized, hard-to-replicate nature of lab space and long-term leases provide some insulation, but share prices can still move with rates. So when evaluating a life science REIT, consider its leverage, debt maturities, and how rate conditions may interact with the biotech funding climate. Past performance doesn't guarantee future results; verify current conditions.
Why is lab space hard to replace if a tenant leaves?
Lab space can be harder to re-lease than ordinary commercial real estate if a life-science tenant departs, and the reason is its specialization. A laboratory is purpose-built with advanced HVAC and ventilation, redundant high-capacity power, specialized gas and water systems, vibration isolation, and other infrastructure that conventional businesses don't need and may not want to pay for. So while the specialized buildout makes existing lab tenants sticky — relocating is costly and disruptive — it also narrows the pool of potential replacement tenants to other lab users, who tend to cluster in the same innovation hubs. In a strong market with healthy biotech demand, a well-located lab building can usually find a new lab tenant; but in a funding downturn, with fewer expanding tenants and rising vacancy, re-leasing specialized space can take longer and require concessions. This re-leasing dynamic is part of why location and cluster quality matter so much: a building in a deep, well-funded hub has a larger pool of potential lab tenants than one in a thin or fading market. So specialization cuts both ways — it retains tenants but can complicate re-leasing when one leaves.
How does Baker 1031 help me evaluate life science REITs?
We help investors understand life science REITs — the specialized lab and research space they own, the biotech and pharma demand behind them, why purpose-built space commands premium rents and sticky tenants, the funding-cycle risk that defines the sector, and the supply pipeline — so you can decide whether the sector fits your goals and access suitable offerings. REIT and non-traded-REIT interests are offered through the broker-dealer, Aurora Securities, Inc. (member FINRA/SIPC), and any recommendation follows a suitability review; non-traded and private REITs typically require accredited or otherwise suitable investors, while publicly traded REITs trade through ordinary brokerage. We help you weigh cluster quality, tenant credit and stage, the supply pipeline, leverage, and funding-cycle exposure, and access suitable offerings when appropriate. Baker 1031 does not provide tax or legal advice — your CPA handles your specific situation, including how REIT dividends are taxed. We discuss demand, returns, and outlook in general, non-promissory terms; yields and returns are never promised, past performance doesn't guarantee future results, and you should verify current conditions. Our role is to help you evaluate life science REITs clearly and invest only when suitable.
Glossary
- Life Science REIT
- A REIT that owns lab and research space leased to biotech and pharma tenants.
- Lab Space
- Purpose-built laboratory real estate engineered for scientific work.
- Wet Lab
- Lab space equipped for experiments using liquids, chemicals, or biologics.
- Innovation Cluster
- A hub where life-science talent, capital, and companies concentrate.
- Biotech
- Companies developing therapies using biological science and technology.
- Pharma Tenant
- A pharmaceutical company leasing research or lab space.
- Venture Capital
- Funding that backs early-stage biotech and shapes lab demand.
- Funding-Cycle Risk
- Demand tied to biotech funding, which rises and falls in cycles.
- Tenant Credit Quality
- The financial strength of a tenant backing the rent.
- Tenant Stage
- Where a tenant sits from early-stage startup to established firm.
- Specialized Infrastructure
- Advanced HVAC, power, and systems that lab space requires.
- Replacement Cost
- The cost to rebuild specialized lab space, which supports rents.
- Sticky Tenant
- A tenant unlikely to move because relocation is costly and disruptive.
- Supply Pipeline
- New lab construction being delivered into a market.
- 90% Distribution Rule
- The REIT requirement to pay out at least 90% of taxable income.
- Suitability Review
- Assessing whether an offering fits the investor before recommending it.
Sources & References
- U.S. Securities and Exchange Commission. Investor.gov — Real Estate Investment Trusts (REITs)
- Nareit. What's a REIT (Real Estate Investment Trust)?
- FINRA. Real Estate Investments
- IRS. About Form 1099-DIV, Dividends and Distributions
Disclosures
This article is published by Baker 1031 Investments, LLC for general educational purposes for accredited investors and is not an offer to sell or a solicitation of an offer to buy any security, nor is it tax, legal, accounting, or investment advice or a recommendation. Any securities offering is made solely through a sponsor’s private placement memorandum (PPM) following a suitability determination. Securities offered through Aurora Securities, Inc. (ASI), member FINRA / SIPC; Baker 1031 Investments is independent of ASI.
Oil & gas mineral and royalty interests and DST programs are speculative, illiquid securities sold only to verified accredited investors and involve substantial risk, including possible loss of principal, commodity-price and production-decline risk, lack of control, and the risk that an intended 1031 exchange fails to qualify for tax deferral. Whether a particular interest qualifies as like-kind real property is a fact-specific legal determination that varies by state and by the terms of the instrument. Tax results depend on your individual circumstances. Consult your own CPA and attorney before acting. Past performance does not guarantee future results.
